Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 34-40, 2023 Feb.
Article
em En
| MEDLINE
| ID: mdl-36282401
ABSTRACT
The impact of treatment on the outcome of chronic myelomonocytic leukemia (CMML) patients over a longer period of time and the potential role of predictive factors are not well defined. In a retrospective observational study, we analyzed 168 CMML patients regarding treatment options and survival during the past three decades. The proportion of patients treated with hydroxyurea (HU), intensive chemotherapy, and azacitidine (AZA) was 65/19/0% before 2000, 51/25/32% from 2000-2010, and 36/12/53% after 2010, respectively. Median overall survival (OS) increased from 10 months before 2000 to 23 months thereafter (pâ¯= 0.021). AZA-treated patients but not patients treated with other treatment options had improved survival as compared to CMML patients without AZA therapy (19 vs. 25 months, pâ¯= 0.041). When looking at subgroups, the following patient cohorts had a significant survival benefit in association with AZA therapy patients with Hbâ¯> 10â¯g/dL, patients with monocytosisâ¯> 10â¯G/L, and patients with mutations in RASopathy genes.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mielomonocítica Crônica
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article